199 related articles for article (PubMed ID: 27055203)
21. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
[TBL] [Abstract][Full Text] [Related]
22. Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease.
Black PN; McDonald CF
Postgrad Med J; 2009 Mar; 85(1001):141-7. PubMed ID: 19351641
[TBL] [Abstract][Full Text] [Related]
23. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
[TBL] [Abstract][Full Text] [Related]
24. Exacerbations of chronic obstructive pulmonary disease.
Wedzicha JA; Donaldson GC
Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
[TBL] [Abstract][Full Text] [Related]
25. [Decision guidance for antibiotic treatment of acute exacerbation of COPD].
Kolditz M; Höffken G
MMW Fortschr Med; 2007 Mar; 149(11):38-40; quiz 41. PubMed ID: 20104700
[TBL] [Abstract][Full Text] [Related]
26. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
27. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.
Leuppi JD; Schuetz P; Bingisser R; Bodmer M; Briel M; Drescher T; Duerring U; Henzen C; Leibbrandt Y; Maier S; Miedinger D; Müller B; Scherr A; Schindler C; Stoeckli R; Viatte S; von Garnier C; Tamm M; Rutishauser J
JAMA; 2013 Jun; 309(21):2223-31. PubMed ID: 23695200
[TBL] [Abstract][Full Text] [Related]
28. The INSPIRE study: influence of prior use and discontinuation of inhaled corticosteroids.
Lanes SF; Jara M
Am J Respir Crit Care Med; 2008 Sep; 178(5):543-4; author reply 544. PubMed ID: 18713851
[No Abstract] [Full Text] [Related]
29. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
[TBL] [Abstract][Full Text] [Related]
30. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
Ohar JA; Donohue JF
Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
[TBL] [Abstract][Full Text] [Related]
31. A score to predict short-term risk of COPD exacerbations (SCOPEX).
Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
[TBL] [Abstract][Full Text] [Related]
32. Predictors of treatment with antibiotics and systemic corticosteroids for acute exacerbations of asthma and chronic obstructive pulmonary disease in primary care.
Salwan AA; Spigt M; Laue J; Melbye H
BMC Fam Pract; 2015 Mar; 16():40. PubMed ID: 25887285
[TBL] [Abstract][Full Text] [Related]
33. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
Wang J; Nie B; Xiong W; Xu Y
J Clin Pharm Ther; 2012 Apr; 37(2):204-11. PubMed ID: 21740451
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of exacerbations of chronic obstructive pulmonary disease].
Urso DL; Luchetti L
Recenti Prog Med; 2007 Mar; 98(3):181-3. PubMed ID: 17484166
[TBL] [Abstract][Full Text] [Related]
35. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
Suh DC; Lau H; La HO; Choi IS; Geba GP
Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
[TBL] [Abstract][Full Text] [Related]
36. Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease.
Cazzola M
Pulm Pharmacol Ther; 2006; 19(2):79-89. PubMed ID: 15964228
[TBL] [Abstract][Full Text] [Related]
37. [Etiological and exacerbation factors for COPD. Respiratory tract infections].
Kaneko T
Nihon Rinsho; 2016 May; 74(5):747-51. PubMed ID: 27254940
[TBL] [Abstract][Full Text] [Related]
38. Effect of albuterol on expiratory resistance in mechanically ventilated patients.
Kondili E; Alexopoulou C; Prinianakis G; Xirouchaki N; Vaporidi K; Georgopoulos D
Respir Care; 2011 May; 56(5):626-32. PubMed ID: 21276320
[TBL] [Abstract][Full Text] [Related]
39. Shortness of breath--is it chronic obstructive pulmonary disease?
McDonald CF
Aust Fam Physician; 2005 Jul; 34(7):541-5. PubMed ID: 15999164
[TBL] [Abstract][Full Text] [Related]
40. Treatment of patients hospitalized for exacerbations of chronic obstructive pulmonary disease: comparison of an oral/metered-dose inhaler regimen and an intravenous/nebulizer regimen.
Shortall SP; Blum J; Oldenburg FA; Rodgerson L; Branscombe JM; Harrow EM
Respir Care; 2002 Feb; 47(2):154-8. PubMed ID: 11812271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
